Comparable stake leader
—
SEC ownership of Zynerba Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001621443.
Disclosed value leader
—
Comparable rows
0/0
Latest evidence
—
- Parsed ownership sources
-
13F, 13D/G, and Forms 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Issuer CIK
- 0001621443
- Issuer location
- Devon, PA
Ownership snapshot
Top shareholders of Zynerba Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
—
Disclosed value leader
—
Comparable rows
0/0
Latest evidence
—
No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 20 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to Zynerba Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
Daniel L. Kisner
Net 12M change
$0
Latest report
10 Oct 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Daniel L. Kisner | Director | Mixed | 10 Oct 2023 | |||
| Armando Anido | Chairman & Chief Exec. Officer, Director | Mixed | 10 Oct 2023 | |||
| John P. Butler | Director | Mixed | 10 Oct 2023 | |||
| William J. Federici | Director | Mixed | 10 Oct 2023 | |||
| Kenneth I. Moch | Director | Mixed | 10 Oct 2023 | |||
| Albert P. Parker | Chief Legal Officer | Mixed | 10 Oct 2023 | |||
| Jones Kenneth T. | Vice President, Corporate Controller and Interim Chief Financial Officer | Mixed | 10 Oct 2023 | |||
| Brian Rosenberger | VP, Commercial & Business Dev. | Mixed | 10 Oct 2023 | |||
| Terri B. Sebree | President | Mixed | 10 Oct 2023 | |||
| James E. Fickenscher | Chief Financial Officer | Mixed | 10 Oct 2023 | |||
| Warren D. Cooper | Director | Mixed | 10 Oct 2023 | |||
| Pamela Stephenson | Director | Mixed | 10 Oct 2023 |
Recent insider transactions for Zynerba Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.